359 related articles for article (PubMed ID: 12438541)
1. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
2. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Steinberg R; Alonso R; Rouquier L; Desvignes C; Michaud JC; Cudennec A; Jung M; Simiand J; Griebel G; Emonds-Alt X; Le Fur G; Soubrié P
J Pharmacol Exp Ther; 2002 Dec; 303(3):1180-8. PubMed ID: 12438542
[TBL] [Abstract][Full Text] [Related]
3. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
5. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
6. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
7. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat.
Magraner J; Pinto FM; Anselmi E; Hernandez M; Perez-Afonso R; Martín JD; Advenier C; Candenas ML
Br J Pharmacol; 1998 Jan; 123(2):259-68. PubMed ID: 9489614
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
Br J Pharmacol; 1997 Jun; 121(4):773-81. PubMed ID: 9208147
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
12. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.
Emonds-Alt X; Doutremepuich JD; Heaulme M; Neliat G; Santucci V; Steinberg R; Vilain P; Bichon D; Ducoux JP; Proietto V
Eur J Pharmacol; 1993 Dec; 250(3):403-13. PubMed ID: 7509286
[TBL] [Abstract][Full Text] [Related]
15. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
17. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.
Cascieri MA; Ber E; Fong TM; Sadowski S; Bansal A; Swain C; Seward E; Frances B; Burns D; Strader CD
Mol Pharmacol; 1992 Sep; 42(3):458-63. PubMed ID: 1383685
[TBL] [Abstract][Full Text] [Related]
20. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
